Camzyos

(Mavacamten)

ApprovedSmall molecule

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Mavacamten is used to treat a heart condition called hypertrophic cardiomyopathy, where the heart muscle becomes abnormally thick, making it harder for the heart to pump blood effectively.[2] Camzyos is currently approved and in use across 5 indications[4].[1]

Camzyos is one of 106 small molecule programs targeting Hypertrophic Cardiomyopathy. It is currently in Approved.

Indications

Total Trials

Active Trials

105

Competitors

FDA Applications

NDA/BLA/ANDA regulatory filings

Patents

Pipeline

Status by Indication[4][1]

Indication

Hypertrophic CardiomyopathyRecruiting

Heart FailureApproved

Cardiovascular DiseaseActive, not recruiting

Cardiomyopathy, HypertrophicActive, not recruiting

Obstructive Hypertrophic Cardiomyopathy (ohcm)Not yet recruiting

Hypertrophic CardiomyopathyApproved

Recruiting

Heart FailureApproved

Approved

Cardiovascular DiseaseApproved

Active, not recruiting

Cardiomyopathy, HypertrophicApproved

Active, not recruiting

Obstructive Hypertrophic Cardiomyopathy (ohcm)Approved

Not yet recruiting

Competition

Competitive Landscape

206 competitors in Heart Failure

#DrugCompanyPhaseTrials

Camzyos

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Approved

35 2

Bayer Aspirin

Bayer

Preclinical

2 3

Brethine

Sanofi

Preclinical

1 4

Medrol

Pfizer

Preclinical

1 5

Amidate

Pfizer

Preclinical

1 6

Zemplar

Adriamycin

Savaysa

Xifaxan

2 10

Oraverse

LLife Extension Foundation Inc.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2026

Recruiting

Mavacamten

NCT06023186

Q4 2026

Recruiting

Hypertrophic Cardiomyopathy

NCT06146660

Recruiting

Cardiomyopathy

NCT07541833

Q2 2027

Recruiting

Pregnancy

NCT05939700

ApprovedActive, not recruiting

Cardiomyopathy, Hypertrophic

NCT06112743

Recruiting

Outcome

NCT06551129

Clinical

Trials by Indication[1]

Hypertrophic Cardiomyopathy15 trials

Extension Study of Mavacamten (MYK-461) in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy Previously Enrolled in PIONEER

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 2·NCT03496168·13 enrolled

A Study of Mavacamten in Adults With Obstructive Hypertrophic Cardiomyopathy in India (ROVER)

Recruiting· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 4·NCT07004972·50 enrolled

A Phase 2 Study of Mavacamten in Adults With Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy (nHCM)

Completed·MMyoKardia, Inc.·Phase 2·NCT03442764·59 enrolled

Show 12 more trials

Clinical Study to Evaluate Mavacamten (MYK-461) in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy

Completed·MMyoKardia, Inc.·Phase 3·NCT03470545·251 enrolled

Myocardial Perfusion Changes Following Optimal Medical Treatment in Symptomatic Hypertrophic Cardiomyopathy

Recruiting·MMedical University of Vienna··NCT07150299·20 enrolled

A Study to Assess the Safety of Mavacamten in Korean Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy

Recruiting· Bristol-Myers Squibb logo

Bristol-Myers Squibb··NCT06146660·600 enrolled

A Study to Evaluate Mavacamten in Adolescents With Symptomatic Obstructive Hypertrophic Cardiomyopathy

Active, not recruiting· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 3·NCT06253221·44 enrolled

A Study to Assess the Real-World Effectiveness of Mavacamten in Adult Patients With Obstructive Hypertrophic Cardiomyopathy in China

Recruiting· Bristol-Myers Squibb logo

Bristol-Myers Squibb··NCT07361289·500 enrolled

COLLIGO-HCM: A Multinational Observational Study of the Real-World Effectiveness of Mavacamten Among Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM)

Active, not recruiting· Bristol-Myers Squibb logo

Bristol-Myers Squibb··NCT06372457·500 enrolled

Mavacamten in Obstructive Hypertrophic Cardiomyopathy

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb··NCT07168655·163 enrolled

Mavacamten Post-marketing Surveillance in Patients With Obstructive Hypertrophic Cardiomyopathy in Japan

Recruiting· Bristol-Myers Squibb logo

Bristol-Myers Squibb··NCT07383025·200 enrolled

A Study to Assess the Treatment of Obstructive Hypertrophic Cardiomyopathy (oHCM) With Mavacamten in the US

Active, not recruiting· Bristol-Myers Squibb logo

Bristol-Myers Squibb··NCT07107373·150 enrolled

Efficacy of Mavacamten in Patients With Symptomatic Latent Obstructive Hypertrophic Cardiomyopathy

Active, not recruiting·XXu Liu·N/A·NCT06947590·78 enrolled

Efficacy of Mavacamten Combined With Radiofrequency Ablation in Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy

Not yet recruiting·SShanghai Chest Hospital·N/A·NCT06856265·40 enrolled

A Study of Mavacamten in Obstructive Hypertrophic Cardiomyopathy

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 3·NCT05414175·38 enrolled

Mavacamten9 trials

A Study to Evaluate the Effects on the Single-Dose Drug Levels of Mavacamten in Healthy Participants

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1·NCT05362045·158 enrolled

A Study to Assess the Effects on the Single-Dose Drug Levels of Mavacamten in Healthy Participants

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1·NCT05658146·95 enrolled

Study Evaluating the Pharmacokinetics of Mavacamten in Healthy Adult Chinese Subjects

Completed·LLianBio LLC·Phase 1·NCT05135871·45 enrolled

Show 6 more trials

A Study to Evaluate Mavacamten in Adults With Symptomatic Obstructive HCM Who Are Eligible for Septal Reduction Therapy

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 3·NCT04349072·112 enrolled

A Study to Evaluate the Effects of Mavacamten in Healthy Participants

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1·NCT05719805·84 enrolled

Effect of Mavacamten Treatment on Coronary Flow Reserve in oHCM

Recruiting·MMichael Ayers··NCT06023186·20 enrolled

A Study of Mavacamten in Participants With HFpEF and Elevation of NT-proBNP With or Without Elevation of cTnT

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 2·NCT04766892·30 enrolled

A Study to Evaluate the Effect of Activated Charcoal With Sorbitol on the Single-dose of Mavacamten in Healthy Participants

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1·NCT05320094·45 enrolled

A Long-Term Safety Extension Study of Mavacamten in Adults Who Have Completed MAVERICK-HCM or EXPLORER-HCM

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 2/3·NCT03723655·314 enrolled

Cardiomyopathy, Hypertrophic2 trials

A Randomized, Double-blind, Placebo-controlled Clinical Study to Evaluate Mavacamten in Adults With Symptomatic Non-obstructive Hypertrophic Cardiomyopathy

Terminated· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 3·NCT05582395·580 enrolled

MEMENTO - A Phase 4, Single-arm, Open-label Clinical Study to Evaluate Mavacamten in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy to Assess the Impact on Myocardial Structure With Cardiac Magnetic Resonance Imaging (CMR)

Active, not recruiting· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Approved·NCT06112743·63 enrolled

Outcome1 trial

Real-world Patient Reported Outcomes Among Patients Treated With Camzyos

Recruiting· Bristol-Myers Squibb logo

Bristol-Myers Squibb··NCT06551129·118 enrolled

Effectiveness1 trial

Real-World Effectiveness of Mavacamten in Canada

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb··NCT06338202·115 enrolled

7 more indications

Cohort Study1 trial

A Retrospective Cohort Study of Mavacamten Patient Support Program in Canada

Active, not recruiting· Bristol-Myers Squibb logo

Bristol-Myers Squibb··NCT06549608·685 enrolled

Pregnancy1 trial

Mavacamten Pregnancy Surveillance Program

Recruiting· Bristol-Myers Squibb logo

Bristol-Myers Squibb··NCT05939700·20 enrolled

Efficacy and Safety1 trial

A Study to Evaluate the Efficacy and Safety of Mavacamten in Chinese Adults With Symptomatic Obstructive HCM

Completed·LLianBio LLC·Phase 3·NCT05174416·81 enrolled

Hypertrophic Cardiomyopathy (HCM)1 trial

The Therapeutic Value of Mavacamten in Hypertrophic Cardiomyopathy With Mid-to-Apical Left Ventricular Obstruction: A Prospective, Interventional, Real-World Clinical Study.

Enrolling by invitation·SSecond Affiliated Hospital, School of Medicine, Zhejiang University·Approved·NCT07103655·132 enrolled

Obstructive Hypertrophic Cardiomyopathy (oHCM)1 trial

Efficacy and Safety of a Left Ventricular Ejection Fraction-Guided Mavacamten Dose Up-Titration Strategy in Chinese Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy: A Prospective, Multicenter, Open-Label Study

Not yet recruiting·SSecond Affiliated Hospital of Nanchang University·Approved·NCT07807384·115 enrolled

Obstructive Hypertrophic Cardiomyopathy1 trial

Deliver Insights in Hypertrophic Cardiomyopathy and Observational Outcomes in Real World: United States and European Prospective Registry Study

Recruiting· Bristol-Myers Squibb logo

Bristol-Myers Squibb··NCT05489705·1,700 enrolled

Cardiomyopathy1 trial

A Study Evaluating Effectiveness and Treatment Patterns of Mavacamten in Patients With Obstructive Hypertrophic Cardiomyopathy Treated With Cibenzoline in Japan (MANAGE-HCM)

Recruiting· Bristol-Myers Squibb logo

Bristol-Myers Squibb··NCT07541833·36 enrolled

Regulatory

FDA Approval Timeline[5]

Apr 28, 2022

CAMZYOS

NDA NDA214998

Apr 28, 2022

CAMZYOS

NDA NDA214998

Nov 22, 2022

CAMZYOS

NDA NDA214998

Jan 13, 2023

CAMZYOS

NDA NDA214998

Dec 19, 2023

CAMZYOS

NDA NDA214998

Apr 30, 2024

CAMZYOS

NDA NDA214998

Apr 17, 2025

CAMZYOS

NDA NDA214998

Sources

References

[1]
ClinicalTrials.gov — 35 trial records for Mavacamten. U.S. National Library of Medicine, National Institutes of Health.
[2]
MedlinePlus Drug Information — Camzyos drug information. U.S. National Library of Medicine, National Institutes of Health.
[3]
ChEMBL — Mavacamten compound record. European Bioinformatics Institute (EMBL-EBI).
[4]
Open Targets Platform — Drug–disease associations for Mavacamten. EMBL-EBI & Wellcome Sanger Institute.
[5]
OpenFDA — FDA approval records (NDA NDA214998). U.S. Food & Drug Administration.
[6]
FDA Orange Book — Patent and exclusivity data for Camzyos. U.S. Food & Drug Administration.
[7]
PubMed — 10 publications indexed for Mavacamten. U.S. National Library of Medicine.
[8]
SEC EDGAR — Karuna Therapeutics, Inc., a Bristol Myers Squibb company company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Mechanism of Action: Cardiac Myosin Inhibitor[3]
Modality: Small molecule[3]
Highest Phase: Approved[1]
Company: KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Patent Landscape[6]

Patent Cliff

Jun 19, 2034

Earliest patent expiration — generic entry possible after this date

Patent #Expires

9585883Jun 19, 2034

RE50050Apr 28, 2036

Key Publications[7]

Efficacy and safety of combined GnRH-a, hysteroscopic surgery, and LNG-IUS for adenomyosis with suboptimal HIFU ablation: a retrospective study.

Int J HyperthermiaDec 1, 2026DOI: 10.1080/02656736.2026.2706037

Plasmapheresis in Hypertriglyceridemia-Associated Acute Pancreatitis: Triglyceride Levels of 5000 mg/dL as a Proposed Threshold.

J Clin ApherAug 1, 2026DOI: 10.1002/jca.70165

Real-World Prognostic Analysis of Clinical Characteristics in Extensive-Stage Small Cell Lung Cancer: A Nomogram for Survival Prediction in Patients Receiving First-Line Immunochemotherapy With Serplulimab.

Cancer MedAug 1, 2026DOI: 10.1002/cam4.72130

Impact of Dietary Fiber Intake on the Immunological Response to Immunotherapy in Cancer Patients: A Scoping Review.

Cancer MedAug 1, 2026DOI: 10.1002/cam4.72108

Oncology Education in Lithuania: An Integrated Curriculum at the Lithuanian University of Health Sciences.

J Cancer EducJul 31, 2026DOI: 10.1007/s13187-026-02958-2

Economic Burden of Type 1 Diabetes in France.

Diabetes Obes MetabJul 30, 2026DOI: 10.1111/dom.71103

Late acquisition of BCR::ABL1 during clonal evolution of SAMD9-associated MDS with phenotypic shift from AML to B-ALL.

Int J HematolJul 30, 2026DOI: 10.1007/s12185-026-04248-5

Beyond Glycaemia: Fear of Hypoglycaemia, Cognition and Functional Mobility After Advanced Hybrid Closed-Loop Therapy in Older Adults With Type 1 Diabetes: A Prespecified Secondary Analysis of a Randomised, Single-Centre Study.

Diabetes Obes MetabJul 30, 2026DOI: 10.1111/dom.71170

Real-World Effectiveness and Safety of Finerenone in People With Type 2 Diabetes and Chronic Kidney Disease: A Spanish Multicentre Retrospective Observational Study (MEDFINE-RWD).

Diabetes Obes MetabJul 30, 2026DOI: 10.1111/dom.71160

Contrast-enhanced ultrasound for diagnosis and follow-up of complicated acute cholecystitis treated with percutaneous cholecystostomy: a case report.

J UltrasoundJul 30, 2026DOI: 10.1007/s40477-026-01178-0

Camzyos

Status by Indication[4][1]

Competitive Landscape

Expected Milestones

Q3 2026

Q4 2026

Q2 2027

Trials by Indication[1]

Hypertrophic Cardiomyopathy15 trials

Mavacamten9 trials

Cardiomyopathy, Hypertrophic2 trials

Outcome1 trial

Effectiveness1 trial

Cohort Study1 trial

Pregnancy1 trial

Efficacy and Safety1 trial

Hypertrophic Cardiomyopathy (HCM)1 trial

Obstructive Hypertrophic Cardiomyopathy (oHCM)1 trial

Obstructive Hypertrophic Cardiomyopathy1 trial

Cardiomyopathy1 trial

FDA Approval Timeline[5]

References

Drug Info

Quick Facts

Patent Landscape[6]

Key Publications[7]

Related News